Statera Biopharma Inc.

Statera Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies aimed at restoring immune balance and homeostasis. Its core focus is on creating novel treatments for conditions where the immune system plays a critical role, such as autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. Utilizing its proprietary Advanced Immunomodulating Multi-Component System (AIMS) platform, Statera Biopharma integrates diverse pharmacological factors including potency, selectivity, and pharmacokinetic-pharmacodynamic relationships to engineer its therapies. The company’s portfolio features late-stage candidates, with products in development for indications like Crohn's disease, hematological conditions, and inflammatory diseases. Additionally, Statera’s pipeline incorporates toll-like receptor (TLR) agonists and antagonists designed to modulate immune responses. Through these efforts, Statera Biopharma seeks to establish a new paradigm in immunotherapy by addressing complex diseases with comprehensive and safety-focused drug profiles, positioning itself within the biotechnology and pharmaceutical research sectors as an innovator in immune system modulation.